Dateline City:
WHITEHOUSE STATION, N.J.
Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68
2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential Venezuelan Bolivar Devaluation and Certain Other Items; 2014 Full-Year GAAP EPS Target of $4.44 to $4.77
2014 Full-Year Non-GAAP EPS Target Includes $0.06 to $0.09 Anticipated Dilution From Planned Sale of Merck Consumer Care and Research Collaboration With Bayer, and Planned Acquisition of Idenix
Generated Worldwide Sales of $10.9 Billion, a Decrease of 1 Percent, Reflecting Unfavorable Impact of Patent Expiries, Divested Products and Decline in Sales of Hepatitis C Products
Grew Top Five Franchises by 6 Percent in Total
Pembrolizumab (MK-3475), an Investigational Anti-PD-1 Antibody, Accepted in Second Quarter for Regulatory Review in Both the United States and European Union
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced financial results for the second quarter of 2014.
Language:
English
Contact:
MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-423-4187orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more